title: Controversies in Barrett esophagus.
abstract: Barrett esophagus develops when metaplastic columnar epithelium predisposed to develop adenocarcinoma replaces esophageal squamous epithelium damaged by gastroesophageal reflux disease. Although several types of columnar metaplasia have been described in Barrett esophagus, intestinal metaplasia with goblet cells currently is required for a definitive diagnosis in the United States. Studies indicate that the risk of adenocarcinoma for patients with nondysplastic Barrett esophagus is only 0.12% to 0.38% per year, which is substantially lower than previous studies had suggested. Nevertheless, the incidence of esophageal adenocarcinoma continues to rise at an alarming rate. Regular endoscopic surveillance for dysplasia is the currently recommended cancer prevention strategy for Barrett esophagus, but a high-quality study has found no benefit of surveillance in preventing deaths from esophageal cancer. Medical societies currently recommend endoscopic screening for Barrett esophagus in patients with multiple risk factors for esophageal adenocarcinoma, including chronic gastroesophageal reflux disease, age of 50 years or older, male sex, white race, hiatal hernia, and intra-abdominal body fat distribution. However, because the goal of screening is to identify patients with Barrett esophagus who will benefit from endoscopic surveillance and because such surveillance may not be beneficial, the rationale for screening might be made on the basis of faulty assumptions. Endoscopic ablation of dysplastic Barrett metaplasia has been reported to prevent its progression to cancer, but the efficacy of endoscopic eradication of nondysplastic Barrett metaplasia as a cancer preventive procedure is highly questionable. This review discusses some of these controversies that affect the physicians and surgeons who treat patients with Barrett esophagus. Studies relevant to controversial issues in Barrett esophagus were identified using PubMed and relevant search terms, including Barrett esophagus, ablation, dysplasia, radiofrequency ablation, and endoscopic mucosal resection.
authors.affiliation: Department of Medicine, VA North Texas Healthcare System, and the Department of Medicine, Division of Gastroenterology and Hepatology, University of Texas Southwestern Medical Center at Dallas. Electronic address: Kerry.Dunbar@utsouthwestern.edu.
authors.forename: Kerry B
authors.initials: KB
authors.lastname: Dunbar
authors.affiliation: Department of Medicine, VA North Texas Healthcare System, and the Department of Medicine, Division of Gastroenterology and Hepatology, University of Texas Southwestern Medical Center at Dallas.
authors.forename: Stuart Jon
authors.initials: SJ
authors.lastname: Spechler
mesh_terms: D055011:Ablation Techniques; D000230:Adenocarcinoma / Q000473:pathology / Q000517:prevention & control; D001471:Barrett Esophagus / Q000175:diagnosis / Q000601:surgery; D003661:Decision Support Techniques; D055088:Early Detection of Cancer; D004938:Esophageal Neoplasms / Q000473:pathology / Q000517:prevention & control; D004945:Esophagoscopy; D006801:Humans; D018579:Patient Selection; D011230:Precancerous Conditions / Q000175:diagnosis / Q000473:pathology / Q000601:surgery; D012008:Recurrence; D016896:Treatment Outcome